PIPELINE

Main projects in clinical development stages.

AnGes‐Origin Project (Drug) As of November 1, 2016

Code /
Project Indication Area Development Stage
Dosage Form

Phase 3 (completed), 
Critical Limb Ischemia JP
Physician‐led study (ongoing)*
AMG0001
(Arteriosclerosis Obliterans
Injection
& Buerger's Disease)
HGF Plasmid US Preparing Phase 3
（Beperminogene
Perplasmid） AMG0001
Primary Lymphedema JP Phase 1/2 (ongoing)
Injection

AMG0001 Ischemic Heart Disease 
US Phase 1 (completed)
Injection (IHD)

AMG0101
Atopic Dermatitis JP Phase 3 completed**  
Ointment
NF‐kB Decoy Oligonucleotide
AMG0101
Disc Degeneration US Preparing Phase 1/2
Injection

AGMG0201
DNA Vaccine Injection
Hypertension Preparing Phase 1 (Australia)

* Drug application under conditional approval system is planned for HGF Plasmid in Japan.
** The study did not show statistically significant difference between the NF‐κB Decoy Oligonucleotide treated group and the placebo group in the primary endpoint.

AnGes‐Origin Project (Medical Device)
Code /
Project Indication Area Development Stage
Dosage Form

AMG0102
Drug Coated Prevention of
NF‐kB Decoy Oligonucleotide PTA Balloon  Vascular Restenosis
JP Clinical study (ongoing)
Catheter

In‐Licensed Project
Code /
Project Indication Area Development Stage
Dosage Form

Physician‐led study (ongoing)
GLBL101c Cervical Precancerous  AnGes acquired the development & marketing 
CIN Therapeutic Vaccine Oral Drug Lesion
JP
rights for Japan, US, England and China from 
BioLeaders (South Korea)

Other In‐Licensed Projects
・Cancer Treatment Drug (Allovectin) [Vical, Inc. (US), development and marketing rights for Asia］
・DNA Vaccine Equine Polyclonal Antibody Therapy for Ebola virus [Vical, Inc. (US), development and marketing rights for Japan］

Products (Approved) 
Product Name Dosage Form Indication Area

AnGes acquried the development and marketing 

Intravenous 
Naglazyme® Infusion 
Muco‐polysaccharidosis VI JP rights of Japan from Biomarin Pharmaceutical, Inc. 
(US) 
Alliance   As of November 1, 2016

Project Indication Area Partner

Critical Limb Ischemia JP Mitsubishi Tanabe Pharma 
HGF Plasmid
(Arteriosclerosis Obliterans
（Beperminogene perplasmid）
& Buerger's Disease) US Mitsubishi Tanabe Pharma

Atopic Dermatitis World Shionogi

NF‐kB Decoy Oligonucleotide Prevention of

Vascular Restenosis JP Medikit
(Drug Coated PTA Balloon Catheter)